CSTL - CIK 0001447362
CASTLE BIOSCIENCES INC trades as CSTL. In its fiscal 2025 annual report the company posted revenue of $344.23M, up 3.7% from the prior year and net income of -$24.16M. This page tracks CASTLE BIOSCIENCES INC through 828 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 7 fiscal years CASTLE BIOSCIENCES INC's revenue grew from $22.79M to $344.23M, a compound annual growth rate of 47.4%. Net profit margin expanded from -27.9% to -7.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-27 |
| Insider trade | 4 | 2026-05-27 |
| Insider trade | 4 | 2026-05-27 |
| Insider trade | 4 | 2026-05-27 |
| Insider trade | 4 | 2026-05-27 |
| Insider trade | 4 | 2026-05-27 |
| Insider trade | 4 | 2026-05-27 |
| Insider trade | 4 | 2026-05-26 |
The largest companies sharing CASTLE BIOSCIENCES INC's SEC industry classification (services-medical laboratories).
CASTLE BIOSCIENCES INC reported revenue of $344.23M for fiscal year 2025, an increase of 3.7% year over year.
In its latest fiscal year CASTLE BIOSCIENCES INC reported a net loss of $24.16M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.